Last reviewed · How we verify

[14C]AZD5718 Oral Suspension

AstraZeneca · Phase 1 active Small molecule

[14C]AZD5718 Oral Suspension is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development. Also known as: [14C]AZD5718.

At a glance

Generic name[14C]AZD5718 Oral Suspension
Also known as[14C]AZD5718
SponsorAstraZeneca
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about [14C]AZD5718 Oral Suspension

What is [14C]AZD5718 Oral Suspension?

[14C]AZD5718 Oral Suspension is a Small molecule drug developed by AstraZeneca.

Who makes [14C]AZD5718 Oral Suspension?

[14C]AZD5718 Oral Suspension is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is [14C]AZD5718 Oral Suspension also known as anything else?

[14C]AZD5718 Oral Suspension is also known as [14C]AZD5718.

What development phase is [14C]AZD5718 Oral Suspension in?

[14C]AZD5718 Oral Suspension is in Phase 1.

Related